| |
S100A12
|
sRAGE
|
Resistin × S100A12
|
Resistin/sRAGE
|
S100A12/sRAGE
|
WBCs
|
N
|
CRP
|
|---|
|
Resistin
|
0.552***
|
-0.507***
|
0.889***
|
0.866***
|
0.696***
|
0.500***
|
0.695***
|
0.613***
|
|
S100A12
| |
-0.252*
|
0.777***
|
0.376**
|
0.734***
|
0.339***
|
0.347***
|
0.321**
|
|
sRAGE
| | |
-0.374***
|
-0.575***
|
-0.547***
|
-0.533***
|
-0.614***
|
-0.566***
|
|
S100A12 × Resistin
| | | |
0.701***
|
0.771***
|
0.385***
|
0.530***
|
0.448***
|
|
Resistin/sRAGE
| | | | |
0.782***
|
0.542***
|
0.734***
|
0.668***
|
|
S100A12/sRAGE
| | | | | |
0.529***
|
0.609***
|
0.567***
|
|
WBCs
| | | | | | |
0.523***
|
0.449***
|
|
N
| | | | | | | |
0.639***
|
- sRAGE, soluble receptor for advanced glycation end products; WBCs, white blood cells; N, neutrophils; CRP, C-reactive protein. Control variables were age and gender. *Correlation significant at the 0.05 level (2-tailed); **correlation significant at the 0.01 level (2-tailed); ***correlation significant at the 0.001 level (2-tailed).
